Section 232 Pharmaceutical Tariffs 2026: The Complete Guide for Importers Before September 29

On April 2, 2026, exactly one year after Liberation Day, President Trump issued a proclamation under Section 232 of the Trade Expansion Act of 1962 imposing sweeping new tariffs on every patented pharmaceutical product and associated ingredient imported into the United States. The default rate is 100% ad valorem. The tariffs apply to every patented drug listed in the FDA’s Orange Book or Purple Book, every active pharmaceutical ingredient, and every key starting material for such products. For 17 named companies the tariffs take effect on July 31, 2026. For every other pharmaceutical importer in the world, the deadline is September 29, 2026. These Section 232 pharmaceutical tariffs 2026 were not struck down by the Supreme Court’s February 2026 IEEPA ruling. Section 232 operates under separate legal authority that the court did not touch. These tariffs are permanent until affirmatively removed. This guide covers the complete tiered rate structure, which companies and products are affected, every exemption pathway that reduces your rate, and the four actions every pharmaceutical importer must complete before September 29.

Section 232 Pharmaceutical Tariffs 2026: In Plain Language What They Actually Do

The pharmaceutical industry has operated for decades under assumptions the Section 232 pharmaceutical tariffs 2026 have ended under the assumption that drug imports into the US face low or zero tariffs. That assumption ends September 29, 2026 for every company that has not secured an agreement with the Trump administration. A patented drug manufactured in India, Germany, Ireland, or Switzerland that previously entered the US at zero or near-zero duty now faces a default 100% tariff. Not 25%. Not 50%. One hundred percent of the entered value of every covered product on every entry.

The stated rationale is national security. The Department of Commerce investigation found that US reliance on imported patented pharmaceuticals and APIs constitutes a threat to national security because supply chain disruptions could limit access to life-saving medications. The policy mechanism is a tariff regime designed simultaneously to reshore pharmaceutical manufacturing, restructure drug pricing through Most-Favored-Nation agreements, and use tariff leverage as a tool of industrial policy. Whatever the policy intent, the operational reality for every pharmaceutical importer is the same: landed cost calculations built before April 2, 2026 are wrong. Every procurement decision made on pre-tariff economics needs to be revisited before September 29.

Section 232 Pharmaceutical Tariffs 2026: Complete Tiered Rate Structure

The proclamation establishes five distinct tariff rate tiers. Understanding which tier applies to your specific company, product, and country of origin is the first and most commercially significant compliance task:

Three critical technical rules about how these rates interact:

• All-inclusive treatment for most rates: For the 100%, 20%, and 15% rates, the Section 232 tariff is all-inclusive, meaning it replaces the MFN base duty rather than stacking on top of it. If your product has an existing MFN rate of 5% and the applicable Section 232 rate is 15%, you pay 15%, not 20%. If the MFN rate exceeds the Section 232 rate, only the MFN rate applies
• UK exception to all-inclusive treatment: The 10% UK rate is explicitly not all-inclusive. UK-origin products pay 10% Section 232 on top of whatever MFN rate already applies. This is the only country where stacking occurs and it means the effective rate for UK pharma importers exceeds 10%
• Lowest applicable rate governs: If a product is subject to more than one duty rate under the proclamation, the lowest rate applies. A company with an onshoring agreement importing EU-origin products would apply the 0% rate rather than the 15% EU rate if 0% is available to them

Section 232 Pharmaceutical Tariffs 2026: Which Products Are Covered

The proclamation covers three product categories, all defined by reference to Annex I which modifies the HTSUS across more than 130 subheadings in Chapters 29 (organic chemicals) and 30 (pharmaceutical products):

• Patented pharmaceutical articles: Products subject to a valid, unexpired US patent that are listed in the FDA Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) or FDA Purple Book (Lists of Licensed Biological Products). This covers branded small molecule drugs and biologics currently under patent protection. If your product is in the Orange Book or Purple Book and under patent, it is in scope
• Active pharmaceutical ingredients (APIs): The active chemical or biological substances that produce the therapeutic effect of a drug. Every API associated with a covered patented pharmaceutical is subject to Section 232 tariffs regardless of whether the API itself is patented
• Key starting materials: Precursor chemicals used in the synthesis of APIs. The supply chain implications extend beyond finished drugs and APIs to the upstream chemical inputs used in their manufacture

What Is Excluded From Section 232 Pharmaceutical Tariffs 2026

The exclusions are specific and commercially significant. Importers of the following product categories are not subject to Section 232 pharmaceutical tariffs at this time:

• Generic pharmaceuticals: FDA-approved drugs that are not subject to a valid, unexpired US patent and are off exclusivity, including products approved under abbreviated new drug applications (ANDAs), 505(b)(2) applications where therapeutically equivalent to a listed drug, biosimilar applications, and authorised generic applications where imported by a generic manufacturer. This is the most commercially significant exclusion. The majority of pharmaceutical import volume by unit count consists of generics
• Biosimilars: Expressly excluded alongside generics
• Orphan drugs: Products approved exclusively for orphan-designated indications treating rare diseases are excluded
• US-origin products: Pharmaceutical products manufactured in the United States are not subject to the tariffs
• Annex IV zero-rate products: Specific HTSUS codes covering pharmaceutical chemicals, vitamins, hormones, antibiotics, and other pharmaceutical preparations are listed in Annex IV with a zero tariff rate. These Annex IV products are also exempt from the Section 122 surcharge
• Additional specialty exclusions: Nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, antibody-drug conjugates, certain medical countermeasures, and some animal health products are excluded subject to the administration’s criteria

Critical warning on generic exclusion durability: The proclamation directs the Secretary of Commerce to review within one year whether circumstances indicate a need to extend Section 232 tariffs to generic pharmaceuticals and associated ingredients. Companies with generic portfolios should not plan on permanent exclusion. The one-year review creates a potential cliff for generics in 2027.

Section 232 Pharmaceutical Tariffs 2026: The Four Annexes Every Importer Must Review

The proclamation has four annexes that determine how the rate structure applies to your specific situation:

• Annex I: The complete list of covered HTSUS subheadings across Chapters 29 and 30. If your product’s 10-digit HTSUS code is not in Annex I, it is not subject to Section 232 pharmaceutical tariffs. This is the first check every importer must complete
• Annex II: 13 companies that entered into company-specific agreements with the Secretary of Commerce before April 2, 2026. These companies have individual tariff terms that may differ from the standard tier structure. If your company is in Annex II, your applicable rate is set by your specific agreement
• Annex III: 17 named large pharmaceutical companies facing the accelerated July 31, 2026 effective date. If your company is in Annex III, you have been operating under Section 232 tariffs since July 31. If you are not in Annex III and have not secured an agreement, your tariffs begin September 29
• Annex IV: HTSUS codes subject to a zero tariff rate under the proclamation. Review Annex IV before assuming a covered HTSUS code triggers tariff liability. Products in Annex IV are also exempt from the Section 122 surcharge currently in force

Section 232 Pharmaceutical Tariffs 2026 Country by Country: Who Pays What

Country of origin is the second most important variable after company agreement status in determining your applicable rate. The pharmaceutical supply chain runs through India, Germany, the UK, Ireland, Switzerland, China, Japan, and South Korea. Here is the rate picture for each major pharma origin market:

• India: Faces the default 100% tariff as of September 29, 2026 unless a company-specific agreement is in place. India is the world’s largest producer of generic pharmaceuticals by volume and the primary supplier of APIs to branded drug manufacturers globally. For Indian generic manufacturers the exclusion applies. For Indian companies manufacturing or supplying APIs for US-patented drugs, the 100% rate applies. India is a major supplier of APIs to US-bound patented drug manufacturers. The Section 232 tariff represents a structural break in the economics of every API supply contract with an Indian manufacturer that does not have a company-specific agreement
• Germany and EU member states: The 15% all-inclusive rate applies. This is the most commercially favourable outcome short of a company-specific agreement. German pharmaceutical companies supplying patented drugs or APIs to US importers face 15% rather than 100%. The EU pharmaceutical industry lobbied extensively for this outcome through the trade deal framework. For importers sourcing from EU contract manufacturers, the country of origin must be confirmed as an EU member state to claim the 15% rate
• UK: 10% rate under the proclamation. On April 2, 2026, USTR announced the UK pharmaceutical pricing deal was finalised, which Arnold and Porter confirms means UK pharmaceutical products will likely face a pathway to 0% when tariffs are imposed. The nominal 10% rate is the proclamation baseline but the finalised UK pricing agreement creates a strong argument for 0% from the effective date. UK-origin pharmaceutical importers should confirm the status of the finalised agreement before September 29
• Switzerland and Liechtenstein: 15% all-inclusive rate. Roche, Novartis, and other Swiss-based pharmaceutical companies benefit from this rate under the framework
• Japan: 15% all-inclusive rate. Major Japanese pharmaceutical companies including Takeda and Astellas are in the 15% tier
• South Korea: 15% all-inclusive rate. Korean pharmaceutical companies including Samsung Biologics benefit from the trade deal rate
• China: Faces the default 100% tariff stacking on top of existing Section 301 tariffs. China is a major supplier of pharmaceutical raw materials and key starting materials. The combined effective tariff burden on Chinese-origin pharmaceutical ingredients is the highest of any major supplier country
• Ireland: 15% all-inclusive rate as an EU member state. Ireland hosts manufacturing operations for many of the world’s largest branded drug companies. US importers sourcing from Irish contract manufacturers benefit from the EU rate

Section 232 Pharmaceutical Tariffs 2026: Three Exemption Pathways to Reduce Your Rate

Pathway 1: Company-Specific Agreement (Annex II)

Thirteen companies secured company-specific agreements with the Secretary of Commerce before April 2, 2026 and are listed in Annex II. These agreements set company-specific tariff rates that may differ from the standard tier structure. The proclamation delegates to the Secretary of Commerce authority to enter into similar agreements in the future. Companies seeking company-specific agreements must approach Commerce directly. The agreements appear to involve commitments on domestic drug pricing aligned with Most-Favored-Nation pricing principles and domestic manufacturing investment. The specific terms of each Annex II agreement have not been publicly disclosed in full.

Pathway 2: Onshoring Plan Plus MFN Pricing Agreement (0% until January 20, 2029)

Companies that secure both a Secretary of Commerce-approved onshoring plan committing to relocate pharmaceutical production to the United States and a Most-Favored-Nation pricing agreement face a 0% tariff rate until January 20, 2029. This is the most favourable outcome available short of an Annex II company-specific agreement. The onshoring plan criteria are being established by Commerce and HHS through a Federal Register notice process. Companies interested in this pathway should monitor Commerce Federal Register publications for the formal criteria and application process. The MFN pricing agreement element requires a commitment to offer US government payers pricing no higher than the lowest price offered to comparable foreign government payers.

Pathway 3: Onshoring Plan Only (20% rate until April 2, 2030)

Companies with a Commerce-approved onshoring plan but no MFN pricing agreement face a 20% rate rather than 100%. This rate applies from September 29, 2026 and remains at 20% until April 2, 2030, at which point it increases to 100% if the onshoring commitment has not been fulfilled. The four-year window at 20% is designed to give manufacturers time to build or transition US-based production while maintaining commercially viable import economics. Companies that begin the onshoring plan application process now and receive Commerce approval before September 29 can enter the 20% tier from the effective date rather than defaulting to 100% and subsequently applying for reclassification.

Section 232 Pharmaceutical Tariffs 2026 and Your Supply Chain: The Operational Reality

The structural problem most pharmaceutical importers face is that their supply chain decisions are made years in advance. Drug product manufacturing agreements, API supply contracts, and key starting material sourcing are typically three to five year commitments. The 145-day window between April 2 and September 29 is not enough time to restructure a pharmaceutical supply chain. It is enough time to assess your exposure, pursue available exemption pathways, and model your landed cost under the applicable tier.

Three specific supply chain decisions that need immediate reassessment:

• India API supply contracts: Every supply agreement with an Indian API manufacturer needs a landed cost recalculation at 100%. For many branded drug supply chains, the Indian API represents a significant proportion of the drug’s cost of goods. At 100% tariff, the economics of the India-US API corridor are fundamentally changed for patented drug supply chains. Generic API supply is excluded and unaffected
• Contract manufacturing organisation (CMO) country selection: Companies with flexibility in CMO selection for new products or at contract renewal should now model the tariff impact of EU, UK, and trade deal country CMOs against Indian and Chinese alternatives. A 15% all-inclusive rate from an EU CMO may produce lower landed cost than a 100% rate from an Indian CMO even if the Indian manufacturing cost is lower per unit
• FTZ and bonded warehouse strategies: US Foreign Trade Zones allow deferral of duty payment until goods enter US commerce. Pharmaceutical importers with FTZ access can defer the Section 232 tariff until the drug is withdrawn from the zone and enters the US market. For products with uncertain regulatory timelines or variable US demand, FTZ admission defers the cash flow impact of the tariff rather than eliminating it. This is a working capital management tool rather than a cost reduction strategy

Section 232 Pharmaceutical Tariffs 2026: Four Actions Before September 29

1. Review Annex I against your complete active HTSUS code portfolio. Annex I lists every HTSUS subheading subject to Section 232 pharmaceutical tariffs 2026 across Chapters 29 and 30. For each covered code, confirm whether your products qualify as patented (Orange Book or Purple Book listed and under valid unexpired patent). Simultaneously review Annex IV for zero-rate exemptions that may apply. Our Global Trade Compliance team conducts pharmaceutical tariff impact assessments against the Annex I and Annex IV lists for active import portfolios
2. Assess your eligibility for the onshoring plan and MFN pricing exemption pathways. If your company has any plans for US manufacturing investment, the onshoring plan application process should begin immediately. Commerce has not yet published the formal criteria but has signalled intent to do so. Companies that demonstrate credible manufacturing commitments before September 29 may qualify for the 20% rate or 0% rate rather than defaulting to 100%. The retroactive penalty risk for fraud or deliberate misrepresentation in onshoring plans is explicitly provided for in the proclamation. Any onshoring plan must be genuine and executable
3. Recalculate your complete landed cost for every covered product at the applicable tier rate. Replace every pre-April 2026 landed cost calculation for covered products with a calculation reflecting the applicable Section 232 rate. Pricing agreements, transfer pricing arrangements, and supply contracts negotiated before April 2 that do not account for the tariff create financial exposure between the effective date and the contract renegotiation date. Identify every contract where you bear the tariff cost but have no contractual mechanism to pass it through or renegotiate it
4. Confirm your IOR structure in each destination country is prepared for the new tariff reality. The Section 232 pharmaceutical tariff is paid by the what an Importer of Record does determines who pays the Section 232 tariff on the US customs entry. For pharmaceutical companies using a specialist IOR services provider for US imports, confirm that the IOR has the correct tier rate coded for each covered product, that the applicable Annex II or onshoring plan status is documented in the entry filing instructions, and that the ACE entry process reflects the correct HTSUS classification aligned with the proclamation’s Annex I structure

Section 232 Pharmaceutical Tariffs 2026: Adjacent Investigations That Could Expand Scope

The White House Fact Sheet accompanying the April 2 proclamation noted that Section 232 investigations are ongoing in sectors adjacent to pharmaceuticals: personal protective equipment, medical consumables, medical equipment and devices, and robotics. These investigations could produce additional Section 232 tariff proclamations in 2026 and 2027. For importers of medical devices, diagnostic equipment, surgical supplies, and healthcare robotics, the pharmaceutical tariff proclamation should be read as the first wave of a broader healthcare supply chain tariff programme rather than an isolated action. Medical device importers should begin their own HTSUS portfolio assessment now rather than waiting for a separate proclamation.

How Carra Globe Supports Pharmaceutical Importers Under Section 232 Pharmaceutical Tariffs 2026

Carra Globe provides IOR services and Global Trade Compliance for pharmaceutical, biotech, and life sciences companies importing into the United States from India, the EU, the UK, Japan, South Korea, and 170+ additional markets. Our compliance team conducts Section 232 pharmaceutical tariff impact assessments covering Annex I and Annex IV review, tier rate determination by company status and country of origin, landed cost recalculation for all covered products, and documentation requirements for onshoring plan and MFN agreement exemption pathways. Our Delivered Duty Paid service incorporates the applicable Section 232 tier rate into full landed cost calculations for pharmaceutical imports before any procurement commitment. For the broader US tariff landscape that pharmaceutical importers are navigating simultaneously, see our guides to the Section 122 tariff 2026, the SCOTUS IEEPA ruling, and the Section 301 investigations 2026.

Frequently Asked Questions: Section 232 Pharmaceutical Tariffs 2026

Are generic pharmaceuticals subject to Section 232 pharmaceutical tariffs 2026?

No, for now. Generic pharmaceuticals, biosimilars, and their associated ingredients are expressly excluded from Section 232 pharmaceutical tariffs 2026. However the proclamation directs Commerce to review within one year whether to extend tariffs to generics. Companies with generic portfolios should not plan on permanent exclusion. The one-year review creates a potential cliff in 2027.

Did the SCOTUS IEEPA ruling affect the Section 232 pharmaceutical tariffs 2026?

No. The Supreme Court’s February 2026 ruling struck down tariffs imposed under IEEPA. The Section 232 pharmaceutical tariffs are issued under Section 232 of the Trade Expansion Act of 1962, a completely separate legal authority. Freshfields, Norton Rose Fulbright, and Mayer Brown all confirm that these tariffs are not within the scope of the tariffs addressed by the SCOTUS ruling. Section 232 authority was not challenged and remains fully intact.

What is the difference between the July 31 and September 29 Section 232 pharmaceutical tariffs 2026 effective dates?

July 31 applies to the 17 large companies listed in Annex III, representing the accelerated 120-day implementation window. September 29 is the 180-day date that applies to all other pharmaceutical importers. If your company is not in Annex III and has not secured an Annex II company-specific agreement, September 29 is your effective date. Check Annex III immediately to confirm your status.

How does the UK pharmaceutical tariff rate work under the Section 232 pharmaceutical tariffs 2026?

The EU 15% rate is all-inclusive, meaning it replaces the existing MFN tariff rate rather than stacking on top of it. The UK 10% rate is explicitly not all-inclusive. It stacks on top of whatever MFN rate already applies to the UK-origin product. In practice this means the effective rate for UK-origin pharmaceutical imports is the MFN rate plus 10%, typically resulting in an effective rate of around 10-12% for most pharma categories. Calculate per product using the specific HTSUS MFN rate plus 10%.

Not under the current proclamation, which covers patented pharmaceuticals, biologics, APIs, and key starting materials under specific HTSUS subheadings in Chapters 29 and 30. Medical devices are classified under different HTSUS chapters. However, Section 232 investigations on medical consumables, medical equipment and devices, and PPE are explicitly ongoing. A separate proclamation covering medical devices is possible in 2026 or 2027. Medical device importers should begin their own HTSUS portfolio review rather than assuming permanent exemption.